# OnCusp Therapeutics

> OnCusp Therapeutics is a privately held clinical-stage oncology company that licenses promising preclinical molecules, develops clinical evidence and seeks pharmaceutical partners for further development and commercialization. Its lead candidate, CUSP06, is an experimental CDH6-directed antibody-drug conjugate in Phase 1 testing; CUSP02 is an early-discovery bispecific antibody program.

- **Founded:** 2021
- **Headquarters:** Princeton, United States
- **Founders:** Bing Yuan (Co-Founder and Chief Executive Officer), Eric Slosberg (Co-Founder and Chief Development Officer), Andy Fu (Co-Founder and Chief Business Officer)
- **Products:** CUSP06 (formerly AMT-707), CUSP02
- **Notable:** USD 139 million cumulative seed and Series A financing reported., FDA IND clearance for CUSP06 announced in August 2023., First CUSP06 Phase 1 patient dosing announced in March 2024.

## Products & services

- **CUSP06 (formerly AMT-707)** — Investigational CDH6-directed ADC with an exatecan payload and drug-to-antibody ratio of eight; Phase 1a/1b study NCT06234423. OnCusp holds rights outside China, with the original agreement specifying outside Greater China.
- **CUSP02** — Early-discovery bispecific antibody designed to address the tumor microenvironment through immune-targeting and anti-angiogenic activity; global rights.

## Achievements

- USD 139 million cumulative seed and Series A financing reported.
- FDA IND clearance for CUSP06 announced in August 2023.
- First CUSP06 Phase 1 patient dosing announced in March 2024.
- FDA Fast Track designation for platinum-resistant ovarian cancer announced in February 2025.
- Initial Phase 1a data presented at ASCO 2025 and Phase 1b data at IGCS 2026.

## Latest updates

- **2026-10** — October 5 announcement: Phase 1b 4.0 mg/kg cohort ORR 62% (13/21), September 23 cutoff; early data, with durability still maturing.
- **2026-05** — Anthony Kim appointed Chief Financial Officer.
- **2025-08** — CUSP06 preclinical research published in Pharmaceutics.
- **2025-06** — Dimitry Nuyten appointed Chief Medical Officer; initial Phase 1a results presented at ASCO.
- **2025-02** — CUSP06 received FDA Fast Track designation for platinum-resistant ovarian cancer.

## Links

- Website: https://www.oncusptx.com/
- LinkedIn: https://www.linkedin.com/company/oncusp-therapeutics/

---

Profile page: https://yespress.io/oncusp-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-10-05